Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920918 · ClinicalTrials.gov registry record · Phase 4
Treatment of Diabetes in Patients With Systolic Heart Failure
A Phase 4 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT02920918 is a Phase 4 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 36 participants.
The verdict
NCT02920918, a Phase 4 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption \[VO2\]) and ventilator efficiency (minute ventilation \[VE\]/carbon dioxide production \[VCO2\] slope) at cardiopulmonary exercise test (CPET) after 12 weeks of active treatment (primary endpoints). Blood pressure (BP), body water content, body composition, cardiac function, and diet will be also measured (secondary endpoints).
Interventions
- DRUG Sitagliptin
- DRUG Canagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02920918
The ClinicalTrials.gov registry entry for NCT02920918 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sitagliptin is the first listed.
NCT02920918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02920918 about?
NCT02920918 is a clinical study titled "Treatment of Diabetes in Patients With Systolic Heart Failure". Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption \[VO2\]) and ventilator efficiency (minute ventilation \[VE\]/carbon dioxide production \[VCO2\] slope) at cardiopulmonary ...
What is the current status of trial NCT02920918?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2016-10. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02920918?
The interventions under investigation include: Sitagliptin (DRUG), Canagliflozin (DRUG).
Who is sponsoring clinical trial NCT02920918?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.